BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trosunilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trosunilimab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07925983-989@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trosunilimab: Phase 1 readout est. (NCT07925983)
DESCRIPTION:Trosunilimab\, phase 1.\nStudy: A Study to Assess How Intraveno
 us and Subcutaneous Administrations of Trosunilimab Move Through the Body 
 of Healthy Adult Participants\nEstimated primary completion: May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trosunilimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07925983
URL:https://assetmemo.bio/drug/trosunilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548542-989@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Trosunilimab: Phase 2 readout est. (NCT06548542)
DESCRIPTION:Trosunilimab\, phase 2.\nStudy: Study of Targeted Therapies for
  the Treatment of Adult Participants With Moderate to Severe Crohn's Disea
 se\nEstimated primary completion: January 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/trosunilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06548542
URL:https://assetmemo.bio/drug/trosunilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697456-989@assetmemo.bio
DTSTAMP:20261121T005006Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Trosunilimab: Phase 2 readout est. (NCT07697456)
DESCRIPTION:Trosunilimab\, phase 2.\nStudy: Study of Advanced Therapies for
  the Treatment of Adult Participants With Moderately to Severely Active Cr
 ohn's Disease or Ulcerative Colitis\nEstimated primary completion: October
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trosunilimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07697
 456
URL:https://assetmemo.bio/drug/trosunilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
